Related Experiment Video
Updated: Aug 29, 2026

Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
ACTIVE-GLU: Personalised modelling of physical activity-driven glucose dynamics in type 1 diabetes under free-living
Ahmad Bilal1, Hood Thabit2,3, Paul W Nutter1
1Department of Computer Science, The University of Manchester, Manchester, UK.
Objective:
Physical activity (PA) lowers blood glucose (BG) levels in individuals with Type 1 Diabetes Mellitus (T1DM), with effects varying by intensity and duration. Predicting BG fluctuations under free-living conditions, beyond structured exercise, helps reduce hypoglycaemia risk. This study aimed to model and predict BG responses across varying PA levels using personalised, activity-informed temporal patterns derived from continuous glucose monitoring (CGM) data.
Methods:
Fourteen adults with T1DM were monitored under free-living conditions using Garmin smartwatches for PA tracking and CGM devices for BG measurement. PA was quantified using step count and maxMotion intensity, and categorised into four levels: low, medium, high, and very high. A 10-day rolling window (moving average) was applied to each participant's data to construct the personalised ACTIVE-GLU model, which estimates mean BG change at 15-minute intervals following PA.
Results:
The ACTIVE-GLU model accurately predicted BG changes across all PA intensities. The lowest average accuracy (81.67%) was observed under low PA, while the highest prediction error occurred during very high PA (MAE = 0.44 mmol/L, RMSE = 0.57 mmol/L, mean bound deviation = 0.38 mmol/L). Bland-Altman analysis confirmed close agreement between predicted and observed BG values, with negligible bias across intensity levels.
Conclusion:
In this exploratory cohort study, quantifying daily PA within a personalised temporal framework enables accurate prediction of BG responses in T1DM under real-world conditions. By incorporating PA intensity into BG dynamics, ACTIVE-GLU provides a personalised, PA-aware framework that may support interpretation of BG trends and inform future decision-support strategies. Future work will validate the model using virtual participants to simulate adaptive dosing interventions.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Type I Diabetes III: Clinical Manifestations
Hypoglycemia and Glucagon
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis